The following is a summary of “Reversal of Factor Xa Inhibitor-Related Intracranial Hemorrhage: A Multicenter, Retrospective, Observational Study Comparing the Efficacy and Safety of Andexanet and ...

Rivaroxaban was first approved in 2011 at a 10-mg dose for the prevention of deep vein thrombosis in those undergoing joint ...

Andexxa (andexanet alfa) is approved for the reversal of anticoagulation by Factor Xa inhibitors – Bayer/Johnson & Johnson's Xarelto (rivaroxaban) and Pfizer/Bristol-Myers Squibb's Eliquis ...

Oral Factor Xa inhibitors, such as apixaban and rivaroxaban, have revolutionized anticoagulation therapy, providing effective stroke prevention and ...

Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action. It has a plasma elimination half-life of 12 hours and has been administered in a twice-daily dosing ...

Rivaroxaban is an orally active direct-acting Factor Xa inhibitor with bioavailability of more than 80%, and a predictable anticoagulant response that obviates the need for routine testing.

Bayer is hoping to position asundexian as a successor to Johnson & Johnson-partnered anticoagulant Factor Xa inhibitor Xarelto (rivaroxaban), its biggest-selling drug, which contributed €3.3 ...

Rivaroxaban, which is most likely to be the first once-daily oral factor Xa inhibitor to be marketed, has already shown superiority to enoxaparin in major orthopaedic surgery.

Researchers sought to compare the effect of abelacimab vs rivaroxaban on risk for bleeding in patients with atrial fibrillation.